# A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy

> **NCT05707377** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **BeOne Medicines** · enrollment: 178 (actual)

## Conditions studied

- Primary Membranous Nephropathy

## Interventions

- **DRUG:** Zanubrutinib
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT05707377
- **Lead sponsor:** BeOne Medicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-17
- **Primary completion:** 2027-10
- **Final completion:** 2027-10
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05707377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05707377, "A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05707377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*